Sivelestat Sodium Hydrate

西维来司钠

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameSivelestat Sodium Hydrate
Drug Alias NameSivelestatum西维来司他sivelestatElaspolEI-546 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeukocyte elastase inhibitors
TargetsLeukocyte elastase
Therapy Area/IndicationsCommunity Acquired PneumoniaSystemic Inflammatory Response SyndromeBlood Coagulation Disorders +[8] 
Global Approved IndicationsSystemic Inflammatory Response SyndromeAcute Lung Injury
Approved Indications in ChinaAcute Lung Injury
Original Approved Country/TerritoryJapan
Original Approved Date2002/04/11
Country/TerritoryBelgiumCanadaUnited States +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesOno Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesStrasbourg University HospitalAffiliated Hospital Of Nantong UniversityOno Pharmaceutical Co Ltd +[4] 
Inactive CompaniesEli Lilly And CompanyShanghai Institute Of Materia Medica, Chinese Academy Of SciencesShanghai Haitian Medicine Technology Development Co Ltd
Active IndicationsSystemic Inflammatory Response SyndromeBlood Coagulation DisordersCoronary Artery Disease +[6] 
Inactive IndicationsCommunity Acquired PneumoniaRespiratory Distress Syndrome, Adult

Other Information

ATC CodeR03
Related LinksWikipediaKEGG